1,036 results on '"Forconi, Francesco"'
Search Results
102. Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial
103. Effects of Ibrutinib on Metabolic Alterations and Micro-Environmental Signalling in Chronic Lymphocytic Leukaemia
104. Genome-wide high resolution DNA profiling of hairy cell leukaemia
105. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome
106. Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis
107. Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array
108. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience
109. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia
110. A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction
111. BRAF Mutations in Hairy-Cell Leukemia
112. B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage
113. A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome
114. CLL-088: Neutropenia Analysis of Venetoclax Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Pooled Data from VENICE-I and -II Phase 3b Trials
115. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
116. Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.
117. Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells
118. IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution
119. Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL
120. Immunogenetics features and genomic lesions in splenic marginal zone lymphoma
121. Predicting the clinical course of Hodgkin lymphoma
122. Correction: Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter’s syndrome: therapeutic implications
123. MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3
124. Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia
125. Mannosylation of the Tumor Immunoglobulin Variable Region Informs Cell of Origin and Environmental Interactions in DLBCL Subsets
126. High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients
127. Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia
128. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia
129. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
130. IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia
131. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
132. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors
133. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis
134. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study
135. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion
136. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis
137. High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia
138. BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia
139. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia
140. The occurrence and significance of V gene mutations in B cell—Derived human malignancy
141. Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch
142. Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency
143. Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses
144. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia
145. Acalabrutinib in Patients (pts) with Waldenstrom Macroglobulinemia (WM)
146. International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia
147. Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter’s syndrome: therapeutic implications
148. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia
149. Hedgehog activation in CLL
150. Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.